Cargando…

Epidemiologic Profile of Type-Specific Human Papillomavirus Infection after Initiation of HPV Vaccination

Organized human papillomavirus vaccination (OHPV) in Japan was introduced in 2010 for girls aged 12–16 years who were born in 1994 or later. The rate of OHPV coverage was 70–80%. However, after suspension of the government vaccination recommendation, the coverage dramatically decreased. We aim to in...

Descripción completa

Detalles Bibliográficos
Autores principales: Sekine, Masayuki, Yamaguchi, Manako, Kudo, Risa, J. B. Hanley, Sharon, Hara, Megumi, Adachi, Sosuke, Ueda, Yutaka, Miyagi, Etsuko, Ikeda, Sayaka, Yagi, Asami, Enomoto, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563721/
https://www.ncbi.nlm.nih.gov/pubmed/32751198
http://dx.doi.org/10.3390/vaccines8030425
_version_ 1783595551259885568
author Sekine, Masayuki
Yamaguchi, Manako
Kudo, Risa
J. B. Hanley, Sharon
Hara, Megumi
Adachi, Sosuke
Ueda, Yutaka
Miyagi, Etsuko
Ikeda, Sayaka
Yagi, Asami
Enomoto, Takayuki
author_facet Sekine, Masayuki
Yamaguchi, Manako
Kudo, Risa
J. B. Hanley, Sharon
Hara, Megumi
Adachi, Sosuke
Ueda, Yutaka
Miyagi, Etsuko
Ikeda, Sayaka
Yagi, Asami
Enomoto, Takayuki
author_sort Sekine, Masayuki
collection PubMed
description Organized human papillomavirus vaccination (OHPV) in Japan was introduced in 2010 for girls aged 12–16 years who were born in 1994 or later. The rate of OHPV coverage was 70–80%. However, after suspension of the government vaccination recommendation, the coverage dramatically decreased. We aim to investigate the change in prevalence of HPV infection after the initiation of HPV vaccination. We recruited females aged 20–21 years attending public cervical cancer screening from 2014 to 2017 fiscal years (April 2014 to March 2018). Residual Pap test specimens were collected for HPV testing. We compared the prevalence of HPV type-specific infection between women registered in 2014 (born in 1993–1994, including the pre-OHPV generation) and registered in 2015–2017 (born in 1994–1997, the OHPV generation). We collected 2379 specimens. The vaccination coverage figures were 30.7%, 86.6%, 88.4% and 93.7% (p < 0.01) from 2014 to 2017, respectively. The prevalence of HPV16/18 infection significantly decreased from 1.3% in 2014 to 0% in 2017 (p = 0.02). The three most prevalent types were HPV52, 16 and 56 in 2014, and HPV52, 58 and 56 in 2015–2017, respectively. HPV16 and 33 infection rates decreased. On the other hand, the HPV58 infection rate was obviously increased after OHPV from 0.3% to 2.1%. Our study demonstrates that the prevalence of HPV16/18 infection dramatically decreased and the profile of type-specific HPV infection was changed after OHPV.
format Online
Article
Text
id pubmed-7563721
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75637212020-10-27 Epidemiologic Profile of Type-Specific Human Papillomavirus Infection after Initiation of HPV Vaccination Sekine, Masayuki Yamaguchi, Manako Kudo, Risa J. B. Hanley, Sharon Hara, Megumi Adachi, Sosuke Ueda, Yutaka Miyagi, Etsuko Ikeda, Sayaka Yagi, Asami Enomoto, Takayuki Vaccines (Basel) Article Organized human papillomavirus vaccination (OHPV) in Japan was introduced in 2010 for girls aged 12–16 years who were born in 1994 or later. The rate of OHPV coverage was 70–80%. However, after suspension of the government vaccination recommendation, the coverage dramatically decreased. We aim to investigate the change in prevalence of HPV infection after the initiation of HPV vaccination. We recruited females aged 20–21 years attending public cervical cancer screening from 2014 to 2017 fiscal years (April 2014 to March 2018). Residual Pap test specimens were collected for HPV testing. We compared the prevalence of HPV type-specific infection between women registered in 2014 (born in 1993–1994, including the pre-OHPV generation) and registered in 2015–2017 (born in 1994–1997, the OHPV generation). We collected 2379 specimens. The vaccination coverage figures were 30.7%, 86.6%, 88.4% and 93.7% (p < 0.01) from 2014 to 2017, respectively. The prevalence of HPV16/18 infection significantly decreased from 1.3% in 2014 to 0% in 2017 (p = 0.02). The three most prevalent types were HPV52, 16 and 56 in 2014, and HPV52, 58 and 56 in 2015–2017, respectively. HPV16 and 33 infection rates decreased. On the other hand, the HPV58 infection rate was obviously increased after OHPV from 0.3% to 2.1%. Our study demonstrates that the prevalence of HPV16/18 infection dramatically decreased and the profile of type-specific HPV infection was changed after OHPV. MDPI 2020-07-29 /pmc/articles/PMC7563721/ /pubmed/32751198 http://dx.doi.org/10.3390/vaccines8030425 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sekine, Masayuki
Yamaguchi, Manako
Kudo, Risa
J. B. Hanley, Sharon
Hara, Megumi
Adachi, Sosuke
Ueda, Yutaka
Miyagi, Etsuko
Ikeda, Sayaka
Yagi, Asami
Enomoto, Takayuki
Epidemiologic Profile of Type-Specific Human Papillomavirus Infection after Initiation of HPV Vaccination
title Epidemiologic Profile of Type-Specific Human Papillomavirus Infection after Initiation of HPV Vaccination
title_full Epidemiologic Profile of Type-Specific Human Papillomavirus Infection after Initiation of HPV Vaccination
title_fullStr Epidemiologic Profile of Type-Specific Human Papillomavirus Infection after Initiation of HPV Vaccination
title_full_unstemmed Epidemiologic Profile of Type-Specific Human Papillomavirus Infection after Initiation of HPV Vaccination
title_short Epidemiologic Profile of Type-Specific Human Papillomavirus Infection after Initiation of HPV Vaccination
title_sort epidemiologic profile of type-specific human papillomavirus infection after initiation of hpv vaccination
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563721/
https://www.ncbi.nlm.nih.gov/pubmed/32751198
http://dx.doi.org/10.3390/vaccines8030425
work_keys_str_mv AT sekinemasayuki epidemiologicprofileoftypespecifichumanpapillomavirusinfectionafterinitiationofhpvvaccination
AT yamaguchimanako epidemiologicprofileoftypespecifichumanpapillomavirusinfectionafterinitiationofhpvvaccination
AT kudorisa epidemiologicprofileoftypespecifichumanpapillomavirusinfectionafterinitiationofhpvvaccination
AT jbhanleysharon epidemiologicprofileoftypespecifichumanpapillomavirusinfectionafterinitiationofhpvvaccination
AT haramegumi epidemiologicprofileoftypespecifichumanpapillomavirusinfectionafterinitiationofhpvvaccination
AT adachisosuke epidemiologicprofileoftypespecifichumanpapillomavirusinfectionafterinitiationofhpvvaccination
AT uedayutaka epidemiologicprofileoftypespecifichumanpapillomavirusinfectionafterinitiationofhpvvaccination
AT miyagietsuko epidemiologicprofileoftypespecifichumanpapillomavirusinfectionafterinitiationofhpvvaccination
AT ikedasayaka epidemiologicprofileoftypespecifichumanpapillomavirusinfectionafterinitiationofhpvvaccination
AT yagiasami epidemiologicprofileoftypespecifichumanpapillomavirusinfectionafterinitiationofhpvvaccination
AT enomototakayuki epidemiologicprofileoftypespecifichumanpapillomavirusinfectionafterinitiationofhpvvaccination